Cutler 1993.

Methods	1. Randomized 2. Double blind 3. Three parallel groups ‐ placebo ‐ Ipsapirone 10‐30 mg/d ‐ Lorazepam 2‐6 mg/d 4. Duration: 4 weeks ‐ acute treatment 4 weeks ‐ extended treatment 2 weeks ‐ withdrawal period with a 1‐week placebo lead‐in prior 5. Analysis: LOCF
Participants	1. Diagnosis: GAD (DSM‐III) 2. N = 90 3. Age (mean): placebo = 32.9 Lorazepam = 29.1 Ipsapirone = 31.2 Sex: 62.2% females Setting: outpatients History: excluded any significant psychiatric disorder other than GAD
Interventions	1. Placebo (N = 30) 2. Lorazepam (N = 30) 3. Ipsapirone (N = 30)
Outcomes	1. dropout rates 2. CGI scores 3. HAM ‐A 4. Physisicans Withdrawal Checklist 5. Zung Anxiety Scale 6. HAM‐D
Notes	(a) CGI and HAM‐A not entered into final analysis as means and SDs not reported; (b) only HAM‐A for Ipsapirone vs benzodiazepine entered secondary to means and SDs reported‐week 8 used
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear